Literature DB >> 22167522

Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.

Rinrada Kietadisorn1, Rio P Juni, An L Moens.   

Abstract

Endothelial nitric oxide synthase (eNOS) serves as a critical enzyme in maintaining vascular pressure by producing nitric oxide (NO); hence, it has a crucial role in the regulation of endothelial function. The bioavailability of eNOS-derived NO is crucial for this function and might be affected at multiple levels. Uncoupling of eNOS, with subsequently less NO and more superoxide generation, is one of the major underlying causes of endothelial dysfunction found in atherosclerosis, diabetes, hypertension, cigarette smoking, hyperhomocysteinemia, and ischemia/reperfusion injury. Therefore, modulating eNOS uncoupling by stabilizing eNOS activity, enhancing its substrate, cofactors, and transcription, and reversing uncoupled eNOS are attractive therapeutic approaches to improve endothelial function. This review provides an extensive overview of the important role of eNOS uncoupling in the pathogenesis of endothelial dysfunction and the potential therapeutic interventions to modulate eNOS for tackling endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167522     DOI: 10.1152/ajpendo.00540.2011

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  77 in total

Review 1.  Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Authors:  Soo Lim; Ichiro Sakuma; Michael J Quon; Kwang Kon Koh
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

3.  Combined l-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs.

Authors:  Anna Dikalova; Judy L Aschner; Mark R Kaplowitz; Gary Cunningham; Marshall Summar; Candice D Fike
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-19       Impact factor: 5.464

Review 4.  Associations between structural and functional changes to the kidney in diabetic humans and mice.

Authors:  David W Powell; David N Kenagy; Shirong Zheng; Susan C Coventry; Jianxiang Xu; Lu Cai; Edward C Carlson; Paul N Epstein
Journal:  Life Sci       Date:  2013-06-22       Impact factor: 5.037

5.  Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis.

Authors:  Biljana Musicki; Tongyun Liu; Sena F Sezen; Arthur L Burnett
Journal:  J Sex Med       Date:  2012-05-23       Impact factor: 3.802

Review 6.  Role of folic acid in nitric oxide bioavailability and vascular endothelial function.

Authors:  Anna E Stanhewicz; W Larry Kenney
Journal:  Nutr Rev       Date:  2017-01       Impact factor: 7.110

Review 7.  New insights into male (in)fertility: the importance of NO.

Authors:  B Buzadzic; M Vucetic; A Jankovic; A Stancic; A Korac; B Korac; V Otasevic
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 8.  L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants.

Authors:  Candice D Fike; Marshall Summar; Judy L Aschner
Journal:  Acta Paediatr       Date:  2014-06-20       Impact factor: 2.299

Review 9.  Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival.

Authors:  Cecilia C Low Wang; Jane E B Reusch
Journal:  Am J Cardiol       Date:  2012-11-06       Impact factor: 2.778

10.  Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.

Authors:  Miao Wang; Mary Topalovski; Jason E Toombs; Christopher M Wright; Zachary R Moore; David A Boothman; Hiromi Yanagisawa; Huamin Wang; Agnieszka Witkiewicz; Diego H Castrillon; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-11-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.